Fortress Biotech, Inc. (FBIO)

NASDAQ: FBIO · Real-Time Price · USD
1.610
-0.120 (-6.94%)
At close: Mar 28, 2025, 4:00 PM
1.720
+0.110 (6.83%)
After-hours: Mar 28, 2025, 7:55 PM EDT
-6.94%
Market Cap 44.44M
Revenue (ttm) 81.50M
Net Income (ttm) -57.53M
Shares Out 27.60M
EPS (ttm) -3.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 232,329
Open 1.700
Previous Close 1.730
Day's Range 1.605 - 1.715
52-Week Range 1.360 - 2.890
Beta 1.75
Analysts Strong Buy
Price Target 21.00 (+1,204.35%)
Earnings Date May 14, 2025

About FBIO

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 186
Stock Exchange NASDAQ
Ticker Symbol FBIO
Full Company Profile

Financial Performance

In 2023, Fortress Biotech's revenue was $84.51 million, an increase of 11.58% compared to the previous year's $75.74 million. Losses were -$68.67 million, -27.42% less than in 2022.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for FBIO stock is "Strong Buy." The 12-month stock price forecast is $21.0, which is an increase of 1,204.35% from the latest price.

Price Target
$21.0
(1,204.35% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates

UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA as first and o...

Other symbols: CKPT
2 days ago - GlobeNewsWire

Fortress Biotech, Inc. (FBIO) Q4 2024 Earnings Call Transcript

Fortress Biotech, Inc. (NASDAQ:FBIO) Q4 2024 Earnings Conference Call March 26, 2025 4:30 PM ET Company Participants Jaclyn Jaffe - Senior Director, Corporate Operations Claude Maraoui - Co-Founder, ...

4 days ago - Seeking Alpha

Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights

FDA Approval of Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for Rosacea Emrosi Initial Distribution Ongoing; First Prescriptions Filled Total Revenues for the Full Year Ended D...

Other symbols: DERM
4 days ago - GlobeNewsWire

Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea

Initial distribution of Emrosi to pharmacies ongoing First prescriptions of Emrosi filled SCOTTSDALE, Ariz., March 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Med...

Other symbols: DERM
6 days ago - GlobeNewsWire

Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025

Company to host conference call to discuss financial results and provide a corporate update on March 26, 2025 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a...

Other symbols: DERM
11 days ago - GlobeNewsWire

Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform

FRANKFURT, Germany and MIAMI, March 17, 2025 (GLOBE NEWSWIRE) -- Partex NV and Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company, today announced a strategic ...

13 days ago - GlobeNewsWire

Journey Medical Corporation to Participate in the 37th Annual ROTH Conference

SCOTTSDALE, Ariz., March 12, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and ma...

Other symbols: DERM
18 days ago - GlobeNewsWire

Sun Pharma to Acquire Checkpoint Therapeutics

Will add UNLOXCYT™ (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global onco-derm...

Other symbols: CKPT
20 days ago - PRNewsWire

Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement

WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO) today announced that it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”)...

Other symbols: MBIO
25 days ago - GlobeNewsWire

Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea

DFD-29 (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) achieved the co-primary and all secondary endpoints with no significant safety is...

Other symbols: DERM
25 days ago - GlobeNewsWire

Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida

U.S. FDA approved Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the treatment of inflammatory lesions of rosacea in adults...

Other symbols: DERM
26 days ago - GlobeNewsWire

Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT

Study is the first randomized, controlled trial examining a vaccine's effectiveness in controlling CMV in recipients of HSCT from vaccinated donors

2 months ago - GlobeNewsWire

Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

Conference call and webcast scheduled to take place on Wednesday, February 5, 2025, at 4:30 p.m. E.T. Conference call and webcast scheduled to take place on Wednesday, February 5, 2025, at 4:30 p.m. E...

Other symbols: DERM
2 months ago - GlobeNewsWire

Sentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for CUTX-101 (Copper Histidinate) Product Candidate for Treatment of Menkes Disease

Six-month priority review granted for CUTX-101 copper histidinate with PDUFA target action date set for June 30, 2025 CUTX-101 has potential to be the first FDA-approved treatment for Menkes disease, ...

2 months ago - PRNewsWire

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease

Priority review granted for CUTX-101 with PDUFA target action date set for June 30, 2025 Cyprium is eligible to receive royalties and up to $129 million in aggregate development and sales milestones C...

2 months ago - GlobeNewsWire

Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)

UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous ...

Other symbols: CKPT
3 months ago - GlobeNewsWire

Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Emrosi approved by FDA on November 4 for the treatment of inflammatory lesions of rosacea in adults Cosibelimab PDUFA goal date of December 28 for potential approval to treat metastatic or locally adv...

4 months ago - GlobeNewsWire

Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Biologics License Application for cosibelimab under review by U.S. FDA PDUFA goal date of December 28, 2024 WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint...

Other symbols: CKPT
4 months ago - GlobeNewsWire

Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

U.S. FDA approved Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the treatment of inflammatory lesions of rosacea in adults; launch expected in late Q1 or early Q2 of 2025

Other symbols: DERM
4 months ago - GlobeNewsWire

Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

Journey Medical to host investor conference call on Monday, November 4, 2024, at 8:30 a.m. E.T. Journey Medical to host investor conference call on Monday, November 4, 2024, at 8:30 a.m. E.T.

Other symbols: DERM
5 months ago - GlobeNewsWire

Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference

Poster Presented on Dermal and Systemic Pharmacokinetics of Oral DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) versus Oral Doxycycline 40 mg Capsules (Oracea®) in Healthy Subject...

Other symbols: DERM
5 months ago - GlobeNewsWire

Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

SCOTTSDALE, Ariz., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses o...

Other symbols: DERM
6 months ago - GlobeNewsWire

Fortress Biotech to Participate in October 2024 Investor Conferences

MIAMI, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term val...

6 months ago - GlobeNewsWire

Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements

MIAMI, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance ...

6 months ago - GlobeNewsWire

Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024

Biologics License Application currently under review by U.S. FDA; PDUFA goal date of December 28, 2024 Biologics License Application currently under review by U.S. FDA; PDUFA goal date of December 28,...

Other symbols: CKPT
6 months ago - GlobeNewsWire